首页> 美国卫生研究院文献>Marine Drugs >An Improved High Yield Total Synthesis and Cytotoxicity Study of the Marine Alkaloid Neoamphimedine: An ATP-Competitive Inhibitor of Topoisomerase IIα and Potent Anticancer Agent
【2h】

An Improved High Yield Total Synthesis and Cytotoxicity Study of the Marine Alkaloid Neoamphimedine: An ATP-Competitive Inhibitor of Topoisomerase IIα and Potent Anticancer Agent

机译:海洋生物碱新安非他命的改进的高产总合成和细胞毒性研究:拓扑异构酶IIα和有效抗癌剂的ATP竞争性抑制剂。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recently, we characterized neoamphimedine (neo) as an ATP-competitive inhibitor of the ATPase domain of human Topoisomerase IIα. Thus far, neo is the only pyridoacridine with this mechanism of action. One limiting factor in the development of neo as a therapeutic agent has been access to sufficient amounts of material for biological testing. Although there are two reported syntheses of neo, both require 12 steps with low overall yields (≤6%). In this article, we report an improved total synthesis of neo achieved in 10 steps with a 25% overall yield. In addition, we report an expanded cytotoxicity study using a panel of human cancer cell lines, including: breast, colorectal, lung, and leukemia. Neo displays potent cytotoxicity (nM IC50 values) in all, with significant potency against colorectal cancer (lowest IC50 = 6 nM). We show that neo is cytotoxic not cytostatic, and that neo exerts cytotoxicity by inducing G2-M cell cycle arrest and apoptosis.
机译:最近,我们将新amphimedine(neo)表征为人类拓扑异构酶IIαATPase域的ATP竞争性抑制剂。到目前为止,neo是唯一具有这种作用机理的吡啶ido啶。 neo作为治疗剂发展的一个限制因素是获得足够数量的用于生物学测试的材料。尽管据报道有两种合成neo的方法,但都需要12个步骤,总产率较低(≤6%)。在本文中,我们报告了分10步实现的neo改进的总合成,总产率为25%。此外,我们报告了使用一组人类癌细胞系进行的扩大的细胞毒性研究,其中包括:乳腺癌,结肠直肠癌,肺癌和白血病。 Neo全部显示出强力的细胞毒性(nM IC50值),对结直肠癌具有显着的效力(最低IC50 = 6 nM)。我们表明,neo具有细胞毒性而不是细胞抑制作用,并且neo通过诱导G2-M细胞周期停滞和凋亡发挥细胞毒性作用。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号